['dry eye syndrome']
['reproxalap ophthalmic solution (0.25%)', 'reproxalap ophthalmic solution (0.1%)', 'vehicle ophthalmic solution']

        Inclusion Criteria:

          -  Be at least 18 years of age of either gender and any race;

          -  Have a reported history of dry eye for at least 6 months prior to Visit 1;

          -  Have a history of use or desire to use eye drops for dry eye symptoms within 6 months
             of Visit 1;

        Exclusion Criteria:

          -  Have any clinically significant slit lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation at Visit 1;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have used any eye drops within 2 hours of Visit 1;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 12 months;

          -  Have used cyclosporine 0.05% or lifitigrast 5.0% ophthalmic solution within 90 days of
             Visit 1;

          -  Have any planned ocular and/or lid surgeries over the study period or any ocular
             surgery within 6 months of Visit 1;

          -  Be using or anticipate using temporary punctal plugs during the study that have not
             been stable within 30 days of Visit 1;
      